Tests cabergoline for endometriosis pain and lesion size in adult women
Tests cabergoline against standard treatment in women aged 18 to 64 with endometriosis.
Key facts
- Who runs it
- Hospital Clinico San Carlos
- Where
- Madrid, SpainSee the site
- Trial code
- Registry title
- CARESS Study: Cabergoline for the Reduction of Endometriosis Symptoms and Lesion Size
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 120 people, planned
- Started
- 1 Sept 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 17 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for premenopausal women aged 18 to 40 with confirmed endometriosis and pelvic pain. It tests cabergoline against standard treatment.
- Age
- 18 to 40 years old, and premenopausal. (The registry header lists 18 to 64 years.)
- Sex
- The record is unclear. The sex field says male, but the criteria and summary describe women with endometriosis.
- Disease stage
- Endometriosis confirmed by ultrasound, magnetic resonance imaging or laparoscopy. Pelvic pain for at least 1 month, with a VAS pain score of 3 points or more.
- Earlier treatment
- No treatment with cabergoline in the three months before the study.
Main reasons for not taking part
- Allergy to dopamine agonists, or serious side effects with cabergoline before
- Severe uncontrolled other illness (ASA above III)
- Active thromboembolic disease
- Pregnant or breastfeeding at the start
- Heart valve disorders, fibrotic disorders, impaired liver function, or breast cancer
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Aged between 18 and 40 years old, and premenopausal
- Confirmed diagnosis of endometriosis by ultrasound/magnetic resonance imaging/laparoscopy
- Pelvic pain (≥1 month) assessed using a VAS scale ≥3 points
- No treatment with cabergoline in the three months prior to the start of the study
- BMI between 18 and 35 kg/m²
- No allergy to the treatments
- Consent to participate in the study
- Ability to speak and understand the message
Who cannot take part
- Documented allergy to dopamine agonists or previous serious side effects with cabergoline
- Active thromboembolic disease
- History of heart valve disorders, history of fibrotic disorders, or impaired liver function
- Breast Cancer
- Severe uncontrolled comorbidities (ASA> III)
- Pregnancy or breastfeeding at the start of the study
- Patient unwillingness to participate in the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Spain
- Hospital Clínico San CarlosMadrid, SpainNot yet recruiting
About the trial
What the trial wants to find out
To evaluate the efficacy of cabergoline (0.5 mg twice weekly) in reducing the size of endometriotic lesions and alleviating pelvic pain in women with confirmed endometriosis, compared with a control group receiving standard treatment (dienogest or combined contraceptives) for endometriosis.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- CARESS Study: Cabergoline for the Reduction of Endometriosis Symptoms and Lesion Size
- Plain-language title
- Tests cabergoline for endometriosis pain and lesion size in adult womenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2025-522812-18-00, who can take part
- Record updated
- 17 September 2025